Clene Inc.

Clene Inc. is a U.S.-based pharmaceutical preparations company that also sells dietary mineral supplements through its subsidiary and commercial partners. The company’s reported revenue is currently small and comes mainly from sales of Zinc Factor, Gold Factor, and rMetx ZnAg Immune Boost, while most of its resources remain focused on research and development of drug candidates.

−10 794,0 %

78,5 %

−13 086,5 %

−41,5 %

0.83

— Clene Inc.
	%
Dietary mineral supplements	100% Aqueous zinc-silver and gold mineral supplement products sold directly or through 4Life.
Royalty revenue	0% License-based royalties tied to Gold Factor sales under an exclusive agreement with 4Life.
Drug candidate development	0% Research and development programs aimed at advancing Clene’s therapeutic pipeline.

Clene sells its supplement products through a mix of direct subsidiary sales and a commercial supply/license...

4Life commercial partnerprimary
Buys Zinc Factor and Gold Factor under supply and license arrangements and drives most current product and royalty revenue.
Direct supplement buyerssecondary
Purchasers of rMetx ZnAg Immune Boost through Clene’s wholly owned subsidiary.
Future pharmaceutical end marketsemerging
Potential future patients, prescribers, and healthcare systems for Clene’s drug candidates.

Clene is incorporated in Delaware and operates with subsidiaries in Australia and the Netherlands, reflecting a small...

•Headquartered and incorporated in the United States
•Subsidiaries in Australia and the Netherlands support operations
•No country-level revenue disclosure was provided in the excerpts
•Australia generated R&D tax credits, not operating revenue
•Nasdaq listing creates U.S. capital market exposure

Clene’s near-term strategy is to preserve liquidity while continuing to develop its drug candidates and maintain...

Liquidity preservation and financingshort-term

The company has recurring losses and substantial doubt about going concern, so funding is essential to continue operations.

Cost reductionshort-term

Lowering cash burn extends runway while the company seeks external capital and advances its pipeline.

Pipeline developmentmedium-term

Long-term value depends on converting R&D into viable therapeutic products beyond the current supplement business.

Clene faces acute financing and listing risk because it has sustained losses, negative operating cash flow, and a...

critical

Going concern and liquidity risk

Management states it has incurred significant losses and expects additional losses, with plans dependent on raising new capital.

Scope: Cash runway and financing access
Materiality: high

high

Nasdaq delisting risk

The company received a notice that its market value of listed securities was below the minimum requirement and may be delisted if it does not regain compliance.

Scope: Nasdaq continued listing requirements
Materiality: high

high

Customer and partner concentration

Current revenue depends heavily on 4Life-related supply and license arrangements and timing of purchases.

Scope: Product and royalty revenue
Materiality: high

high

Development and regulatory execution risk

Future value depends on advancing drug candidates through research, development, and eventual commercialization.

Scope: Pipeline programs
Materiality: high

Revenue recognition for supply and royalty agreements

Affects reported revenue and comparability across periods

Fair value of warrants and derivative liabilities

Can materially affect net income without changing cash flow

Convertible notes and contingent earn-out liabilities

Affects liabilities, interest/other income, and dilution analysis

Deferred tax asset valuation allowance

Limits recognition of tax benefits and signals ongoing losses

Clene Inc.

Going concern and liquidity risk

Nasdaq delisting risk

Customer and partner concentration

Development and regulatory execution risk

Zenas BioPharma, Inc.

LENZ Therapeutics, Inc.

Maze Therapeutics, Inc.

Zymeworks Inc.

GOLDENWELL BIOTECH, INC.

REST EZ Inc.